title: Maintenance bevacizumab is associated with increased hemoglobin in patients with advanced, nonsquamous, non-small cell lung cancer.
abstract: We retrospectively analyzed hematologic parameters in 22 patients with advanced, nonsquamous, NSCLC undergoing VEGF inhibition on a phase II clinical trial of bevacizumab, carboplatin, and gemcitabine. We also examined TTP in relation to hemoglobin changes. Median hemoglobin increased significantly from a 12.9 g/dL pretreatment to 13.8 g/dL (p =.01) after the second cycle of maintenance bevacizumab until the first off cycle measurement. There was no difference in TTP in patients who achieved a rise in hemoglobin compared with patients who did not (median 238 days vs. 268 days, p =.38.) Maintenance bevacizumab is associated with increased hemoglobin in advanced, nonsquamous, NSCLC patients.
authors.affiliation: Division of Hematology, Department of Medicine, Stanford University School of Medicine, CA, USA. riessjo@stanford.edu
authors.forename: Jonathan W
authors.initials: JW
authors.lastname: Riess
authors.forename: Aaron C
authors.initials: AC
authors.lastname: Logan
authors.forename: Yelena
authors.initials: Y
authors.lastname: Krupitskaya
authors.forename: Sukhmani
authors.initials: S
authors.lastname: Padda
authors.forename: Christelle
authors.initials: C
authors.lastname: Clément-Duchêne
authors.forename: Kristen
authors.initials: K
authors.lastname: Ganjoo
authors.forename: A Dimitrios
authors.initials: AD
authors.lastname: Colevas
authors.forename: Melanie San
authors.initials: MS
authors.lastname: Pedro-Salcedo
authors.forename: Calvin J
authors.initials: CJ
authors.lastname: Kuo
authors.forename: Heather A
authors.initials: HA
authors.lastname: Wakelee
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000068258:Bevacizumab; D002289:Carcinoma, Non-Small-Cell Lung / Q000097:blood / Q000188:drug therapy* / Q000401:mortality; D004921:Erythropoietin / Q000097:blood; D005260:Female; D006454:Hemoglobins / Q000032:analysis*; D006801:Humans; D008175:Lung Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D006454:Hemoglobins; D042461:Vascular Endothelial Growth Factor A; D004921:Erythropoietin; D000068258:Bevacizumab